RxDoctor Payments Data

Robert Aden, MD

Endocrinology, Diabetes & Metabolism · Miami, FLNPI 1457312829

Payments from drug & device makers

$7,903in general payments, 2019–2025

Across 163 payments — averaging $48.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$5K
  • Boehringer Ingelheim$478
  • Lilly USA, LLC$454
  • Medtronic$400
  • Amarin Pharma, Inc.$345
  • Bayer$219
  • plus $1K from 20 others

What the payments were for

  • Consulting fees$3,84849%
  • Travel & lodging$4305%
  • Food & beverage$3,60846%
  • Education$180%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,903 in reported general payments places this provider in the 60th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.

See all endocrinology, diabetes & metabolism providers in Florida

Medicare billing

Part B allowed, 2024
$79,360
Medicare patients
271
Services billed
829

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide264$313,073
JardianceEmpagliflozin91$107,339
MounjaroTirzepatide34$44,021
FarxigaDapagliflozin Propanediol35$34,401
TrulicityDulaglutide23$26,547
JanuviaSitagliptin Phosphate30$18,699
Fiasp FlextouchInsulin Aspart (Niacinamide)23$14,253
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/711$10,362
RybelsusSemaglutide11$10,163
Tresiba Flextouch U-100Insulin Degludec14$8,251
Novolog FlexpenInsulin Aspart37$5,642
SynthroidLevothyroxine Sodium64$5,108
Admelog SolostarInsulin Lispro17$4,729
Humulin N KwikpenInsulin Nph Human Isophane33$4,029
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog13$3,850

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$4,734$323,236275 claims
Boehringer IngelheimJardiance$478$107,33991 claims
Lilly USA, LLCMounjaro, Trulicity$454$70,56957 claims
AstraZenecaFarxiga$52$34,40135 claims
MerckJanuvia$36$18,69930 claims
AbbVieSynthroid$32$5,10864 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$127$2,238199 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.

Other endocrinology, diabetes & metabolism in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →